Skip to search formSkip to main contentSkip to account menu

KOS 862

Known as: KOS-862, KOS862 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

epothilone D

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies.
2028 Background: KOS-862 (Epothilone D) (K) has shown single agent activity against metastatic breast cancer (MBC) and NSCLC… 
2005
2005
Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer
778 Background: KOS-862 (K) is genetically-produced epothilone D, a naturally occurring macrolide. K has preclinical activity in… 
2005
2005
A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer
7127 Background: KOS-862 is an epothilone produced by recombinant DNA technology. Epothilones act as tubulin stabilizing agents… 
2005
2005
Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors
2041 KOS-862 (a mitotic spindle poison causing G2/M arrest) and GEM (a pyrimidine antimetabolite) are anti-cancer agents with… 
2005
2005
The epothilone dilemma.
Because of their potent antitumor activity, drugs targeting microtubules are among the most commonly prescribed anticancer agents… 
2005
2005
Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors
2049 Background: KOS-862 shares a binding site on tubulin heterodimers with paclitaxel, but shows greater potency in P… 
Review
2005
Review
2005
Activity of epothilones.
Epothilones represent a novel class of anticancer drugs which inhibit the cell cycle and strongly influence cell division. The… 
2004
2004
Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors.
2024 Background: Similar to taxanes, epothilones are a class of naturally occurring cytotoxic macrolides that stabilize… 
2004
2004
Molecular mechanisms involved in paclitaxel-resistance in advanced ovarian cancer
5431 Advanced ovarian cancer is one of the most chemosensitive of all solid tumours to chemotherapy and responses are expected in… 
Review
2004
Review
2004
Epothilone D (Kosan/Roche).
Kosan and Roche are developing the microtubule inhibitor epothilone D (KOS-862 and NSC-703147), an analog of epothilone B for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)